CDSCO To Make IP Mandatory For Isopropyl Alcohol Used In Pharma Application

Mumbai : The Central Drugs Standard Control Organization (CDSCO) is planning to make Indian Pharmacopoeia (IP) mandatory for all isopropyl alcohol used in pharma applications.

It has written to state and Union territory drugs controllers twice seeking their inputs on making IP compulsory for isopropyl alcohol used in drug application.

The CDSCO move comes after a representation from Deepak Fertilizers and Petrochemical Corporation Limited (DFPCL), a leading manufacturer of industrial chemicals in India. DFPCL is the largest and sole manufacturer of isopropyl alcohol in the country catering to 40 per cent of domestic demand.

DFPCL in its representation to the Union health and family welfare ministry stated that pharmaceutical manufacturers are not using IP grade isopropyl alcohol in drug application. This in turn impacts the quality of pharmaceutical products.

However, monograph of isopropyl alcohol is included in Indian Pharmacopoeia as pharmaceutical aid (solvents).

Besides its use in pharma application as solvent, isopropyl alcohol is a key ingredient in hand sanitizer manufacturing.

Isopropyl alcohol is a colorless, flammable chemical compound with a strong odor. It dissolves a wide range of non-polar compounds. It also evaporates quickly, leaves nearly zero oil traces, compared to ethanol, and is relatively non-toxic, compared to alternative solvents. Isopropyl alcohol is esterified to give isopropyl acetate, another solvent.

The health ministry instructed the central drug regulatory authority to take necessary steps to address the issue.

Acting on the health ministry’s instruction, CDSCO decided to make IP mandatory for all isopropyl alcohol used in pharma applications.

It dashed off a letter to state and UT drugs regulators on August 3, 2021seeking their inputs in regard. Due to lack of responses from state and UT drugs controllers, CDSCO again has written to them seeking their comments on the issue on September 13, 2021.

All state and UT drugs controllers are once again requested to submit the information to CDSCO at the earliest, said Dr VG Somani, drugs controller general of India.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’